newsfilter
← Latest News
GlobeNewswire·

Allena Pharmaceuticals Provides Update on Clinical Development Programs

-ALLN-346 successfully completes Phase 1b safety study; on track to start two Phase 2a studies in Q3 2021 with initial data expected in Q4 2021- -Reloxaliase advancing in URIROX-2 Pivotal Phase 3 study; revised interim analysis now targeted for Q1 2